D Francomano1, R Bruzziches, G Barbaro, A Lenzi, A Aversa. 1. Department of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University, Rome, Italy.
Abstract
PURPOSE: Modifications of cardiovascular and metabolic parameters during testosterone (T) replacement and withdrawal have never been investigated in severely obese hypogonadal men. METHODS: Twenty-four severely obese (mean BMI 42; mean age 54.5) hypogonadal men (mean T = 245 ± 52 ng/dL) were enrolled in an observational, parallel-arm, open-label, 54-week study of hypocaloric diet plus physical activity (DPE; n = 12) or DPE plus T injections (DPE + T; n = 12), followed by 24 weeks of DPE alone. Primary endpoints were variations from baseline of cardiovascular (cardiac performance, blood pressure, endothelial function, carotid intima-media thickness, CIMT; epicardial fat thickness, EF) and body composition (fat/lean mass) parameters. Secondary endpoints were variations from baseline of hormonal (T and GH) and metabolic (oral glucose tolerance test, lipids, fibrinogen) parameters. RESULTS: At 54 weeks, DPE + T showed improvements in EF, ejection fraction, diastolic function, CIMT and endothelial function (p < 0.01 vs. controls). Also, hormonal (T, p < 0.0001; GH, p < 0.01), metabolic (HOMA, p < 0.01; microalbuminuria, p < 0.01), lipid (total cholesterol, p < 0.05) and inflammatory (fibrinogen, p < 0.05) parameters improved. After 24 weeks from T withdrawal, all cardiac and hormonal parameters returned to baseline, while fat but not lean mass and blood pressure ameliorations were maintained. An inverse relationship either between EF vs. endothelial function and EF vs. T levels was found (r (2) = -0.46, p < 0.001 and r (2) = -0.56, p < 0.0005, respectively) while direct relationship between T vs. endothelial function occurred (r (2) = 0.43, p < 0.005) in DPE + T. A 33 % dropout rate was reported in DPE without serious adverse events. CONCLUSIONS: In middle-aged hypogonadal obese men, 1-year T treatment was safe and improved cardio-metabolic and hormonal parameters. We firstly demonstrated that T withdrawal determines a return back to hypogonadism within 6 months, with loss of cardiovascular and some body composition improvements attained.
PURPOSE: Modifications of cardiovascular and metabolic parameters during testosterone (T) replacement and withdrawal have never been investigated in severely obese hypogonadalmen. METHODS: Twenty-four severely obese (mean BMI 42; mean age 54.5) hypogonadal men (mean T = 245 ± 52 ng/dL) were enrolled in an observational, parallel-arm, open-label, 54-week study of hypocaloric diet plus physical activity (DPE; n = 12) or DPE plus T injections (DPE + T; n = 12), followed by 24 weeks of DPE alone. Primary endpoints were variations from baseline of cardiovascular (cardiac performance, blood pressure, endothelial function, carotid intima-media thickness, CIMT; epicardial fat thickness, EF) and body composition (fat/lean mass) parameters. Secondary endpoints were variations from baseline of hormonal (T and GH) and metabolic (oral glucose tolerance test, lipids, fibrinogen) parameters. RESULTS: At 54 weeks, DPE + T showed improvements in EF, ejection fraction, diastolic function, CIMT and endothelial function (p < 0.01 vs. controls). Also, hormonal (T, p < 0.0001; GH, p < 0.01), metabolic (HOMA, p < 0.01; microalbuminuria, p < 0.01), lipid (total cholesterol, p < 0.05) and inflammatory (fibrinogen, p < 0.05) parameters improved. After 24 weeks from T withdrawal, all cardiac and hormonal parameters returned to baseline, while fat but not lean mass and blood pressure ameliorations were maintained. An inverse relationship either between EF vs. endothelial function and EF vs. T levels was found (r (2) = -0.46, p < 0.001 and r (2) = -0.56, p < 0.0005, respectively) while direct relationship between T vs. endothelial function occurred (r (2) = 0.43, p < 0.005) in DPE + T. A 33 % dropout rate was reported in DPE without serious adverse events. CONCLUSIONS: In middle-aged hypogonadal obesemen, 1-year T treatment was safe and improved cardio-metabolic and hormonal parameters. We firstly demonstrated that T withdrawal determines a return back to hypogonadism within 6 months, with loss of cardiovascular and some body composition improvements attained.
Authors: Antonio Aversa; Roberto Bruzziches; Davide Francomano; Giuseppe Rosano; Andrea M Isidori; Andrea Lenzi; Giovanni Spera Journal: J Sex Med Date: 2010-10 Impact factor: 3.802
Authors: Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal Journal: JAMA Date: 2006-04-05 Impact factor: 56.272
Authors: Mustafa Toma; Finlay A McAlister; Erin E Coglianese; Venkatesan Vidi; Samip Vasaiwala; Jeffrey A Bakal; Paul W Armstrong; Justin A Ezekowitz Journal: Circ Heart Fail Date: 2012-04-17 Impact factor: 8.790
Authors: Guido A Rosito; Joseph M Massaro; Udo Hoffmann; Frederick L Ruberg; Amir A Mahabadi; Ramachandran S Vasan; Christopher J O'Donnell; Caroline S Fox Journal: Circulation Date: 2008-01-22 Impact factor: 29.690
Authors: João L Cavalcante; Balaji K Tamarappoo; Rory Hachamovitch; Deborah H Kwon; M Chadi Alraies; Sandra Halliburton; Paul Schoenhagen; Damini Dey; Daniel S Berman; Thomas H Marwick Journal: Am J Cardiol Date: 2012-09-14 Impact factor: 2.778
Authors: Caterina Mammi; Matilde Calanchini; Antonella Antelmi; Francesca Cinti; Giuseppe M C Rosano; Andrea Lenzi; Massimiliano Caprio; Andrea Fabbri Journal: Int J Endocrinol Date: 2011-12-22 Impact factor: 3.257
Authors: Silvia Migliaccio; Davide Francomano; Roberto Bruzziches; Emanuela A Greco; Rachele Fornari; Lorenzo M Donini; Andrea Lenzi; Antonio Aversa Journal: Int J Endocrinol Date: 2013-11-20 Impact factor: 3.257
Authors: Katya B Rubinow; Jing H Chao; Derek Hagman; Mario Kratz; Brian Van Yserloo; Nilesh W Gaikwad; John K Amory; Stephanie T Page Journal: Am J Physiol Endocrinol Metab Date: 2017-07-11 Impact factor: 4.310
Authors: G Rastrelli; L Giovannini; A E Calogero; D Gianfrilli; E Serra; A Pizzocaro; V A Giagulli; G Motta; G Vancieri; A Sperandio; S Andò; R Selice; G Luca; F Cocchiara; D Canale; M Maggi Journal: J Endocrinol Invest Date: 2016-04-01 Impact factor: 4.256
Authors: A M Isidori; G Balercia; A E Calogero; G Corona; A Ferlin; S Francavilla; D Santi; M Maggi Journal: J Endocrinol Invest Date: 2014-11-11 Impact factor: 4.256
Authors: D Francomano; G Fattorini; D Gianfrilli; D Paoli; P Sgrò; A Radicioni; F Romanelli; L Di Luigi; L Gandini; A Lenzi; A Aversa Journal: J Endocrinol Invest Date: 2015-07-11 Impact factor: 4.256